NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$199.00
Cat.#: 28118 |
Product Name: Anti-C5AR1(Avdoralimab) Monoclonal Antibody |
Synonyms: C5a-R;C5aR;CD88 |
Description: Anti-C5AR1(avdoralimab ) Monoclonal Antibody |
Background: Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
Applications: Flow Cyt |
Recommended Dilutions: Flow Cyt 1:100 |
Host Species: Homo sapiens |
Isotype: IgG1 |
Purification: Purified from cell culture supernatant by affinity chromatography |
Species Reactivity: Human C5AR1 |
Constituents: Lyophilized from sterile PBS, pH 7.4. 5 % – 8% trehalose is added as protectants before lyophilization. |
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). |
Figure 1. Flow cytometry analysis with 1 µg/mL Anti-C5AR1 (avdoralimab biosimilar) mAb (28118) on Expi293 cells transfected with Human C5AR1 protein (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram). |